CA3023305C - COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES - Google Patents

COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES

Info

Publication number
CA3023305C
CA3023305C CA3023305A CA3023305A CA3023305C CA 3023305 C CA3023305 C CA 3023305C CA 3023305 A CA3023305 A CA 3023305A CA 3023305 A CA3023305 A CA 3023305A CA 3023305 C CA3023305 C CA 3023305C
Authority
CA
Canada
Prior art keywords
dosage form
valerian
pharmaceutical dosage
composition
release portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3023305A
Other languages
English (en)
French (fr)
Other versions
CA3023305A1 (en
Inventor
Syed M. Shah
Christopher Diorio
Daniel Hassan
Fred Hassan
Original Assignee
Societe des Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA filed Critical Societe des Produits Nestle SA
Publication of CA3023305A1 publication Critical patent/CA3023305A1/en
Application granted granted Critical
Publication of CA3023305C publication Critical patent/CA3023305C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3023305A 2016-05-06 2017-05-04 COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES Active CA3023305C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332728P 2016-05-06 2016-05-06
US62/332,728 2016-05-06
PCT/US2017/031046 WO2017192843A1 (en) 2016-05-06 2017-05-04 Valerian composition and related methods

Publications (2)

Publication Number Publication Date
CA3023305A1 CA3023305A1 (en) 2017-11-09
CA3023305C true CA3023305C (en) 2024-07-02

Family

ID=60203773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023305A Active CA3023305C (en) 2016-05-06 2017-05-04 COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES

Country Status (10)

Country Link
US (4) US10342873B2 (enExample)
EP (1) EP3452020A4 (enExample)
JP (2) JP7576905B2 (enExample)
KR (1) KR20190008265A (enExample)
CN (2) CN117482062A (enExample)
AU (1) AU2017260019A1 (enExample)
CA (1) CA3023305C (enExample)
MX (1) MX2018013569A (enExample)
RU (1) RU2018142019A (enExample)
WO (1) WO2017192843A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090315A1 (en) * 2020-01-17 2022-11-23 Société des Produits Nestlé S.A. Dosage form with sustained release melatonin pellets
IT202200013576A1 (it) * 2022-06-27 2023-12-27 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato a rilascio differenziato di melatonina e principi attivi

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699075A1 (fr) * 1992-12-11 1994-06-17 Rech Sarl Ab Préparation médicinale à libération programmable dans le temps notamment à base de plantes.
FR2713636B1 (fr) 1993-12-07 1996-01-05 Adir Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
FR2727315A1 (fr) 1994-11-30 1996-05-31 Cooperative Agricole Laitiere Utilisation d'un decapeptide a activite de type benzodiazepine pour la preparation de medicaments et de complements alimentaires
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
ZA9711051B (en) 1996-12-10 1999-06-09 Bristol Myers Squibb Co Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents
IL147333A0 (en) 1999-07-21 2002-08-14 Ancile Pharmaceuticals Process for the extraction of valerian root
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
CA2470829A1 (en) * 2001-12-20 2003-07-03 Alpex Pharma Sa Particulate compositions
EP1743633B1 (en) 2004-04-06 2010-08-18 Taiyokagaku Co., Ltd. Use of a combination of theanine and serotonin for sleep disorders
EP1758557B1 (en) 2004-05-11 2011-07-13 Egalet Ltd. Swellable dosage form comprising gellan gum
PL1824450T3 (pl) 2004-10-11 2013-04-30 Nasaleze Patents Ltd Kompozycje do podawania donosowego
WO2006137443A1 (ja) 2005-06-22 2006-12-28 Takeda Pharmaceutical Company Limited 難溶性の有効成分を含有する錠剤
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
CN1850212A (zh) * 2006-02-28 2006-10-25 潮州市强基制药厂 一种缬草油液体硬胶囊及其制备方法
BRPI0719442A2 (pt) 2006-09-27 2013-12-03 Finzelberg Gmbh & Co Kg Processo para a preparação de um extrato de valeriana
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US20090197974A1 (en) * 2008-02-05 2009-08-06 Khaleeq Ahmed Natural dietary supplement tablet
US8809395B2 (en) 2009-01-23 2014-08-19 Valericon Gmbh Methods for making valerenic acid derivatives and their use
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
CN102370833B (zh) * 2010-08-17 2014-03-26 北京亚东生物制药有限公司 一种解表祛暑的泡腾剂及其制备方法和用途
CN102058630B (zh) * 2010-12-16 2014-03-19 苏州大学 一种镇静安神的缬草制剂及其制备方法
CN102247443A (zh) * 2010-12-23 2011-11-23 祝凤仪 治疗神经衰弱中药外洗粉、泡腾片的配方及其制备方法
PH12013501512A1 (en) 2011-01-17 2013-09-16 Takeda Pharmaceuticals Co Orally dispersible tablet
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
CN102114060B (zh) * 2011-02-22 2012-12-12 都晓伟 黑水缬草提取物及其制备方法和应用
JP2013053144A (ja) * 2011-08-09 2013-03-21 Daiichi Sankyo Healthcare Co Ltd 鎮静剤組成物
US20130116215A1 (en) * 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
EP2806863B1 (en) 2012-01-26 2017-08-09 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US20150250203A1 (en) 2012-01-26 2015-09-10 Wikifoods, Inc. Enclosing materials in natural transport systems
CA2928777A1 (en) 2012-11-09 2014-06-05 Abattis Bioceuticals Corp. Nitric oxide increasing nutritional supplements and methods
US20140271890A1 (en) 2013-03-14 2014-09-18 Thaer Ahmad Controlled-release pharmaceutical composition
WO2014175852A1 (en) 2013-04-23 2014-10-30 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
PL231923B1 (pl) 2013-10-28 2019-04-30 Proteon Pharmaceuticals Spolka Akcyjna Sposób enkapsulacji materiału zawierającego bakteriofagi, otrzymywana nim mikrokapsułka oraz jej zastosowania
RU2535020C1 (ru) 2014-01-23 2014-12-10 Карпов Алексей Николаевич Фармацевтическая композиция седативного и спазмолитического действия
CA2934595C (en) * 2014-02-06 2022-06-21 Sequential Medicine Limited Composition and method for aiding sleep
MX374677B (es) * 2014-05-05 2025-03-06 Boehringer Ingelheim Int Granulado de disolución rápida.
EP2974733B1 (de) 2014-07-14 2016-09-07 Dr. Willmar Schwabe GmbH & Co. KG Kombination von Baldrianwurzelextrakt und Lavendelöl zur Verwendung zur Behandlung von Schlafstörungen

Also Published As

Publication number Publication date
AU2017260019A1 (en) 2018-11-22
RU2018142019A3 (enExample) 2020-09-16
KR20190008265A (ko) 2019-01-23
CN109310638A (zh) 2019-02-05
CN117482062A (zh) 2024-02-02
US11141485B2 (en) 2021-10-12
JP2022116251A (ja) 2022-08-09
US11141484B2 (en) 2021-10-12
US20190328881A1 (en) 2019-10-31
US20210401990A1 (en) 2021-12-30
RU2018142019A (ru) 2020-06-08
WO2017192843A1 (en) 2017-11-09
JP2019514977A (ja) 2019-06-06
US20170319697A1 (en) 2017-11-09
US20190321475A1 (en) 2019-10-24
JP7577090B2 (ja) 2024-11-01
EP3452020A1 (en) 2019-03-13
CA3023305A1 (en) 2017-11-09
MX2018013569A (es) 2019-03-14
JP7576905B2 (ja) 2024-11-01
BR112018072795A2 (pt) 2019-04-30
EP3452020A4 (en) 2020-02-19
US10342873B2 (en) 2019-07-09
US11701425B2 (en) 2023-07-18

Similar Documents

Publication Publication Date Title
US10888522B2 (en) Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO1995022974A2 (en) Film coated tablet of paracetamol and domperidone
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
US11701425B2 (en) Valerian composition and related methods
AU2020209940A1 (en) Solid micronized melatonin composition
JP5718937B2 (ja) パーキンソン病を治療するための医薬組成物及びその調製方法
WO2024165966A1 (en) Gastroretentive extended release compositions of riociguat
KR20160105662A (ko) 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
BR122021015452B1 (pt) Uso de valeriana e de um agente acidificante na fabricação de uma composição para tratar dor, insônia, ansiedade, deficiência de melatonina, distúrbio de sono e/ou um distúrbio de ritmo circadiano e método para produção de uma forma de dosagem farmacêutica de valeriana estável em armazenamento
BR112018072795B1 (pt) Comprimido ou cápsula consistindo em valeriana dentro de uma matriz polimérica acidificada
KR20210012082A (ko) 미라베그론 및 탐스로신을 포함하는 약학 조성물
JP2024074793A (ja) 医薬組成物
CA2456410A1 (en) Stabilised pharmaceutical composition comprising an extented release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
KR20100102441A (ko) 제어방출형 고혈압 치료제의 조성물 및 그 제조방법
WO2011107922A2 (en) Extended release composition of milnacipran
AU2004200716A1 (en) Stabilised Pharmaceutical Composition Comprising an Extended Release Non-steroidal Anti-inflammatory Agent and an Immediate Release Prostaglandin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504